Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on March 10, 2025
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
GlobeNewswire
·
March 10, 2025
GAITHERSBURG, Md., March 10, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a leading global …
Fusion Biopsy Market to Hit US$0.91 Billion by 2029 with 7.1% CAGR | MarketsandMarkets™.
GlobeNewswire
·
March 10, 2025
Delray Beach, FL, March 10, 2025 (GLOBE NEWSWIRE) -- The global fusion biopsy market, valued at US$0.61 billion in 2023, is forecasted to grow at a robust CAGR of 7.1%, reaching US$0.65 billion in 2024 and an impressive US$0.91 billion by 2029. This growth …
HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications
GlobeNewswire
·
March 10, 2025
Southlake, TX, March 10, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (“AI”)-powered medical technology company focused on transforming ECGs/EKGs to save lives through …
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025…
GlobeNewswire
·
March 10, 2025
PALO ALTO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the …
Longevity Life Advisors Launches CancerEDGE: A Program Offering Advanced Cancer Genomics and Precision Health Services
GlobeNewswire
·
March 10, 2025
Indianapolis, March 10, 2025 (GLOBE NEWSWIRE) -- Longevity Life Advisors announces the launch of CancerEDGE, a first-of-its-kind program designed to provide genomic testing and precision health services. The program offers affordable access to services and …
31 Million Patient Journeys, One Mission
GlobeNewswire
·
March 10, 2025
MINNEAPOLIS, March 10, 2025 (GLOBE NEWSWIRE) -- OneMedNet, an AI-powered Real World Data leader, has announced a collaboration with Datavant, a health data platform, to provide access to tokenized, purpose-built data for life sciences and medical research …
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
GlobeNewswire
·
March 10, 2025
IRVINE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company has received a Notice of Allowance from the U.S. Patent …
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP
GlobeNewswire
·
March 10, 2025
March 10, 2025 Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the way to finalize Phase 3 protocol and recruit sites for U.S. Phase 3 substantially funded by $17.0 million CPRIT grant …
IRADIMED CORPORATION To Participate at the 37th Annual Roth Conference
GlobeNewswire
·
March 10, 2025
WINTER SPRINGS, Fla., March 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that it will participate in the 37th Annual Roth Conference. Iradimed’s CFO, Jack Glenn, and CCO, Jeff Chiprin, will host one-on- …
New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form
GlobeNewswire
·
March 10, 2025
-- As Published in Two Scientific Journals, Findings Open Potential Biomarker Strategy for Patient Response to LB-100 -- PASADENA, CALIF., March 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and …
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights
GlobeNewswire
·
March 10, 2025
- Cash, cash equivalents and short-term investments as of December 31, 2024, and anticipated cost savings from prioritizing ENPP1 Deficiency program, including an approximately 25% workforce reduction, expected to support operations into the first quarter …
CARMELL CORP REBRANDS AS LONGEVITY HEALTH HOLDINGS TO HIGHLIGHT BUSINESS FOCUS & GROWTH STRATEGY
GlobeNewswire
·
March 10, 2025
Pittsburgh, PA, March 10, 2025 (GLOBE NEWSWIRE) -- PITTSBURGH, Mar. 10, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX; CTCXW), a bio-aesthetics company (the “Company”, “we”, “our”, or “us”), today announced a comprehensive corporate rebranding …
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain
GlobeNewswire
·
March 10, 2025
LONDON and NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA …
Stereotaxis to Present at 37th Annual Roth Conference
GlobeNewswire
·
March 10, 2025
ST. LOUIS, March 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the 37th …
Eradivir announces Phase 2 human challenge study of EV25 in healthy adults infected with influenza
GlobeNewswire
·
March 10, 2025
WEST LAFAYETTE, Ind., March 10, 2025 (GLOBE NEWSWIRE) -- Eradivir, a clinical-stage small molecule immunotherapy biotech company, announced it has begun a Phase 2 challenge study with its antiviral therapeutic, EV25. The study will provide safety and …
Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1
GlobeNewswire
·
March 10, 2025
Northstrive Biosciences Inc. has scheduled a pre-IND meeting with the U.S. Food and Drug Administration for April 23, 2025. EL-22 is leveraging a myostatin-engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on …
Talkspace Supports U.S. Navy Pilot to Provide Free Virtual Mental Health Services
GlobeNewswire
·
March 10, 2025
NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- Today Talkspace (NASDAQ: TALK), a leading online behavioral health care company, announced it will support the U.S. Navy’s pilot program to provide access to therapy and mental health resources for approximately …
Sernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Development Officer and Head of R&D
GlobeNewswire
·
March 10, 2025
LONDON, Ontario and BOSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing it’s Cell Pouch Bio-hybrid Organ as a functional cure for type …
Cronos Group Inc. to Speak at the 37th Annual Roth Conference
GlobeNewswire
·
March 10, 2025
TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and CEO, will speak at the 37th Annual …
BetterLife Announces Debt Conversions
GlobeNewswire
·
March 10, 2025
VANCOUVER, British Columbia, March 10, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic …